Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

39

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

39 results for “Lewy Body Disease”

Learn how ShareScore rates datasets ↗
zenodo40/100

Data from: Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases

<p>Tabular raw data corresponding to figure sets used in the study.&nbsp;</p> <p><span>Fig. 1 Mouse &alpha;-syn fibrils are structurally similar to human E46K-mutated and MSA-amplified &alpha;-syn fibrils</span></p> <p><span>Chemical structure and binding curves of ThT (J), Nile Red (K), and FSB (L) to mouse and human sonicated &alpha;-syn fibrils (average radii: 16.68&plusmn;1.44 nm and 15.14&plusmn;4.02 nm, respectively). Data points indicate means from three independent experiments and error bars are S.E.M.&nbsp; ****p&lt;0.0001 and ***p&lt;0.01 from 2-tailed t-tests. </span></p> <p><span>Fig. 2 Distinct &beta;-fold stacking arrangements in mouse &alpha;-syn fibrils contribute to low tensile strength and resilience</span></p> <p><span>(C) Representation of proposed model of fibril fragmentation for tensile strength estimation used to simulate the MMGBSA energy of &alpha;-syn fibrils rupture and group analysis of MMGBSA energy required to disrupt a stack of six rungs. Error bars represent S.D. from 100 independent simulations. (D) Group comparison of fibril breakage under sonication conditions shown as the percent of size population of 10-100 nm (e.g., short fibrils) at 0, 2, and 30 minutes, measured by DLS. Error bars indicate S.E.M of three independent experiments with 30 acquisition measurements corresponding to each experiment. (E) Filter-trap slot-blot analysis of sonicated fibrils (i.e., PFFs) exposed to different concentrations of guanidinium chloride (GuHCl), and then remaining fibrils detected with the fibril-selective antibody MJFR14-6-4-2. Error bars indicate S.E.M from three independent experiments. (F) DLS analysis of PFFs after incubation with GuHCL. Error bars indicate S.E.M of three independent experiments with 10 acquisition measurements for each biological sample. Curves in (E) and (F) show asymmetric sigmoidal models with a goodness of fit &gt;0.96, and&nbsp; **p&lt;0.01, **p&lt;0.001, ****p &lt; 0.0001 from unpaired 2-tailed t-tests.</span></p> <p><br><br></p> <p><span>Fig. 3 Mouse &alpha;-syn fibrils fail to elicit robust cytokine and lysosome damage in macrophages </span></p> <p><span>(B) Internalized Alexa-647-PFFs (%area) inside cells and (C) % of LAMP1-positive vesicles positive for PFFs. Each data point represents the means of cells analyzed from at least eight images from three independent experiments. (D) ELISA analysis of the extracellular IL-6 and (E) CCL5 from MDM cultures treated with PFFs (1 &mu;g/mL) for 3 and 24 hours. Each data point represents the mean from two technical replicates from four independent experiments. (F) % of Gal3-positive vesicles calculated per mm&sup2; of cell surface area in PFF-treated MDM cultures after 24 hours of incubation and (G) % of Gal3-positive vesicles also positive for DQ-PFFs after 48 hours of PFF incubation. Data points show the mean values from cells imaged across three independent experiments with at least eight images analyzed per group. (H) Representative images of Gal3 immunostaining after 24-hours treatment with Alexa-647- or DQ- labeled PFFs. Orthogonal views of sequential z-stacks are shown. Side left image = x,y plane, side right image = y,z plane; top image = x,z plane. Scale bar is 5 um. Error bars represent S.E.M and&nbsp; ***p&lt;0.001, *p&lt;0.05 and ns for not significant from unpaired 2-tailed t-tests (panels B, C, F, G) or from Tukey&rsquo;s post-hoc test after ANOVA (panels D,E). </span></p> <p><span>Fig. 4. Mouse and human &alpha;-syn fibril uptake in neurons is similar and clathrin-dependent</span></p> <p><span>(A) Time-dependent dynamics of pHrodo-labeled mouse or human PFF (1 &micro;g/mL) internalization over 24 hours into human-PAC-wt-SNCA<sup>+/+</sup>/Snca<sup>-/- </sup>hippocampal primary neuronal cultures at DIV7, with normalized pHrodo-channel intensity to DAPI counts at the indicated time point. Each dot represents mean values from four images each from three independent neuronal cultures.&nbsp;</span><span>(D)&nbsp; Alexa-568 intensity in dopaminergic neurons and (E) intensity exclusively in the perinuclear area 8 hours post PFF incubation. Each dot represents the mean value of one image with at least 20 images collected from three independent experiments. (F) Calculated uptake of pHrodo-labeled &alpha;-syn PFFs at 24 hours in the presence of endocytosis inhibitors with signals normalized to vehicle only controls. Each dot in panel F represents the mean value of four images evaluated per condition from three independent experiments. Error bars for each group analysis represent S.E.M., and ns is not-significant from 2-tailed t tests.</span></p> <p><span>Fig. 5. Mouse &alpha;-syn fibrils pathology propagation is more efficient than human &alpha;-syn in primary neurons.&nbsp;</span></p> <p><span>(A) Levels of pS129-&alpha;-syn signal assessed relative to the number of neurons in the corresponding cultures cultured from human-PAC-wt-SNCA<sup>+/+</sup>/Snca<sup>-/- </sup>hippocampal primary neuron culture treated with 1 &micro;g/mL of &alpha;-syn PFFs for 14 days, or equivalent amounts of monomer as indicated, and stained against pS129-&alpha;-syn, Tau and NeuN. (B) To ensure the specificity of pS129-&alpha;-syn signals, control groups show the lack of signal in neurons cultured from Snca<sup>-/- </sup>mice following 14 days of incubation with &alpha;-syn PFFs or monomer as shown.&nbsp;(D) Abundance of distinct pS129-&alpha;-syn signals in cell bodies or neuritic morphology in neuronal cells treated with 1 &micro;g/mL of mouse or human &alpha;-syn PFFs. (E) Proportion of pS129-&alpha;-syn occupancy in cell body and neurites in primary hippocampal cultures incubated with mouse or human &alpha;-syn PFFs for 14 days. (F) ELISA quantification of &alpha;-syn aggregate levels in cell lysates from human-PAC-wt-SNCA<sup>+/+</sup>/Snca<sup>-/- </sup>&nbsp;or Snca<sup>-/- </sup>neuronal cultures treated with fibril PFFs or monomeric protein for 14 days. (G) Group analysis of NeuN-positive nuclei abundance normalized to DAPI count. Each data point in a group in the graphs represents the mean of signal from an individual litter with two technical replicates per litter and at least 25 images analyzed for each replicate, with error bars indicating S.E.M. Significance was determined by 2-tailed t-tests; **p&lt;0.001, ****p &lt; 0.0001, ns for not significant.</span></p> <p><span>Fig. 6. Mouse PFF induced &alpha;-syn pathology spreads through the mouse brain to seed human &alpha;-syn pathology more efficiently than human &alpha;-syn PFFs</span></p> <p><span>(B) Group analysis of &alpha;-syn pathology propagation ratio to contralateral side in piriform cortex, (C) thalamus, and (D) dorsal striatum, quantified as proportion of pSyn neuronal inclusion spread between Ipsi and Contr. areas. (E) Analysis of pS129-&alpha;-syn pathology near the injection site within the ipsilateral dorsal striatum. Each data point (n=5 per group) in group analysis plots represents the mean of the signal from 20-25 sections from an individual animal, and error bars indicate S.E.M. Significance was determined by 2-tailed t-tests; *p&lt;0.05, ns for not significant</span>.</p> <p><span>Fig. 7. Recruitment of human &alpha;-syn monomer into mouse PFFs leads to the generation of mouse-like fibrils.</span></p> <p><span>(A) Representative aggregation assays showing mouse and human PFF-templated aggregation with human &alpha;-syn monomer, with (B) the calculated lag phase. Data points represent normalized ThT fluorescence from three independent experiments with error bars indicating S.E.M. (C) Representative filter-trap slot-blot membranes stained with MJFR14-6-4-2 &alpha;-syn aggregate-specific antibodies for the detection of aggregated &alpha;-syn in corroboration of aggregation kinetics without amyloid dyes.&nbsp;</span><span>&nbsp;(E) Group analysis of ThT binding (fluorescence units, F.U.) from chimeric or homogenous-sequence extracted, monomer-free, sonicated &alpha;-syn fibril (PFF) products, as well as (F) Nile Red binding. Each data point in panels E and F represents a mean from an individual experiment measured in duplicate with three independent experiments.E<a name="_Hlk173655145"></a>rror bars indicate S.E.M.,&nbsp; **p&lt;0.01, from a 2-tailed t-test, and ***p&lt;0.001 from Tukey&rsquo;s post-hoc test after ANOVA. </span></p> <p>fig. S2. High resolution estimation of the cryo-EM map of mouse and human recombinant &alpha;-syn fibrils</p> <p>Fourier shell correlation (FSC) resolution estimation and validation for the 3D reconstruction of the cryo-EM collected images of procured&nbsp; mouse fibrils generated by Duke (a) and EPFL (b) research groups. (c) FSC estimation plot of human &alpha;-syn fibrils collected and generated at Duke University.</p> <p>&nbsp;</p> <p>fig. S7. Generation and validation of mouse and human &alpha;-syn PFFs</p> <p>(c) Group analysis of the size population proportions of sonicated mouse and human &alpha;-syn preparations, (e) representative average radii of human &alpha;-syn,(f) UV absorbance spectra and (g) coefficient extinction adjusted concentration. Each data point or S.E.M in panel c, e and g are extracted from a single acquisition from three independent experiments with ten measurements analyzed per group. Each dot in panel f is the mean of two technical replicates from three independent batches. Significance was assessed via 2-tailed t-tests with ns for not significant.</p> <p>&nbsp;</p> <p>fig. S9. Mouse &alpha;-syn PFFs are highly susceptible to sarkosyl denaturation.</p> <p>(a) Filter-trap slot-blot analysis of sonicated fibrils (PFFs) exposed to different concentrations of sarkosyl (left) and the remaining fibrils detected with the fibril-selective antibody MJFR14-6-4-2 in a dose-response curve (middle), with group analysis between two PFF variants at 1% Sarkosyl compared (right). Error bars indicate S.E.M from three independent experiments. (b) DLS analysis of sonicated fibrils (PFFs) exposed to sarkosyl concentrations in a dose-response curve. Error bars indicate S.E.M of three independent experiments with 10 acquisition measurements for each biological sample.&nbsp; *p&lt;0.05 from unpaired 2-tailed t-tests.</p> <p>&nbsp;</p> <p>fig. S11. Evaluation of &alpha;-syn aggregation ELISA using control recombinant mouse and human &alpha;-syn fibril PFFs.</p> <p>Standard curves generated from mouse and human PFFs in a pan-&alpha;-syn aggregate-specific ELISA. The ELISA approach was utilized to quantify the level of aggregates present in lysates derived from the neuronal cultures. The standard curve, along with the indicated goodness of fit and corresponding r&sup2; values, provides reliable measures at physiological ranges. Each data point represents the mean from three technical replicates from two independent experiments with errors bars indicating S.E.M.</p> <p>&nbsp;</p> <p>fig. S9. Evaluation of &alpha;-syn ELISA using control recombinant mouse and human &alpha;-syn fibril PFFs</p> <p>Standard curve generated from mouse and human PFFs in a pan-&alpha;-syn aggregate ELISA. The ELISA was utilized to quantify the level of aggregates present in the cell lysates. The standard curve, along with the indicated goodness of fit and corresponding r&sup2; values, provides a reliable measure for interpreting the results. Each data point represents the mean from three technical replicates from two independent experiments with errors bars indicating S.E.M.</p> <p>&nbsp;</p> <p>fig. S12. Elevated p-S129-&alpha;-syn levels in iPSC-derived dopaminergic neurons following treatment with mouse &alpha;-syn PFFs</p> <p>(b) Levels of pS129-&alpha;-syn in the &beta;-III-tubulin area in iPSC-derived DA neurons after 7 days of treatment with 10 &mu;g/mL of PFFs or control. (c) The quantity of pS129-&alpha;-syn puncta relative to the &beta;-III-tubulin area measured in each image and compared across conditions. (d) Proportion of abundance of pS129-&alpha;-syn puncta localized in cell bodies and neurites in group analysis between mouse and human &alpha;-syn PFF treatments. Each data point in c and d represent the mean value of the images from one well (n=4) and errors bars indicate S.E.M with **p&lt;0.01 from 2-tailed t-tests.&nbsp;</p> <p>&nbsp;</p> <p>fig. S13. Evaluation of kinetic properties in aggregation assays with cross-seeded chimeric fibrils show that the chimeric fibrils largely replicate the functional properties of their parental seeds, despite different amino acid sequences between the fibril preparations.</p> <p>(a) Representative RT-QuIC (real-time quaking induced)&nbsp; assays of normalized relative fluorescence values (RFUs) with mouse monomer templating on different PFF seeds in the creation of new fibrils. The lack of formation of spontaneous fibrils (gray color, no PFFs added &ldquo;no template&rdquo;) indicate that spontaneous aggregation is not occurring under the given aggregation conditions within the specified timeframes. Line graphs show corresponding lag in amplification (in hours, or time to initial fluorescence threshold) of the different reactions combined with different PFF concentrations added and analyzed to a linear regression model. Data points represent normalized ThT fluorescence to their maximal fluorescence in the individual reactions, accounting for differential ThT binding to different fibril structures. (b) Comparable reactions as above but with human instead of mouse monomer templating with the indicated PFF seed. &nbsp;</p> <p>&nbsp;</p>

opencc-by-4.0May 2024View details →
dryad40/100

Data from: Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort

Open the record for dataset details and reuse information.

publicDec 2025View details →
zenodo36/100

Modeling Lewy Body Disease with SNCA Triplication iPSC-Derived Cortical Organoids and Identifying Therapeutic Drugs

<p><span>This repository contains the source code for the single-cell and single-nuclei RNA sequencing data analysis for the study&nbsp;<strong><span>Modeling Lewy Body Disease with SNCA Triplication iPSC-Derived Cortical Organoids and Identifying Therapeutic Drugs</span></strong>&nbsp;by Yunjung Jin et al.<br></span></p>

opencc-by-4.0Jul 2024View details →
ClinicalTrials.gov36/100

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

ClinicalTrials.gov study NCT03305809. IPD Sharing: YES. Countries: 3. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia

ClinicalTrials.gov study NCT04405596. IPD Sharing: Not stated. Countries: 1. Publications: 20.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies

ClinicalTrials.gov study NCT00855686. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Self and Autobiographical Memory in Dementia With Lewy Bodies and Alzheimer Disease: a Behavioral and Multimodal Neuroimaging Study

ClinicalTrials.gov study NCT04616287. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Epileptic Activity in Patients With Alzheimer's Disease and Lewy Body Dementia

ClinicalTrials.gov study NCT04436341. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease

ClinicalTrials.gov study NCT02268617. IPD Sharing: NO. Countries: 1. Publications: 5.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.

ClinicalTrials.gov study NCT01876459. IPD Sharing: Not stated. Countries: 1. Publications: 6.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad28/100

Data from: Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy Body disease

Objective: Variants in GBA are associated with Lewy Body (LB) pathology. We investigated whether variants in other lysosomal storage disorder (LSD) genes also contribute to disease pathogenesis. Methods: We performed a genetic analysis of four LSD genes including GBA, HEXA, SMPD1, and MCOLN1 in 231 brain autopsies. Brain autopsies included neuropathologically defined LBD without Alzheimer Disease (AD) changes (n = 59), AD without significant LB pathology (n = 71), Alzheimer disease and lewy body variant (ADLBV) (n = 68), and control brains without LB or AD neuropathology (n = 33). Sequencing of HEXA, SMPD1, MCOLN1 and GBA followed by 'gene wise' genetic association analysis was performed. To determine the functional effect, a biochemical analysis of GBA in a subset of brains was also performed. GCase activity was measured in a subset of brain samples (n = 64) that included LBD brains, with or without GBA mutations, and control brains. A lipidomic analysis was also performed in brain autopsies (n = 67) which included LBD (n = 34), ADLBV (n = 3), AD (n = 4), PD (n = 9) and control brains (n = 17), comparing GBA mutation carriers to non-carriers. Results: In a 'gene-wise' analysis, variants in GBA, SMPD1 and MCOLN1 were significantly associated with LB pathology (p range: 0.03–4.14 x10-5). Overall, the mean levels of GCase activity were significantly lower in GBA mutation carriers compared to non-carriers (p&lt;0.001). A significant increase and accumulation of several species for the lipid classes, ceramides and sphingolipids, was observed in LBD brains carrying GBA mutations compared to controls (p range: p&lt;0.05-p&lt;0.01). Interpretation: Our study indicates that variants in GBA, SMPD1 and MCOLN1 are associated with LB pathology. Biochemical data comparing GBA mutation carrier to non-carriers support these findings, which have important implications for biomarker development and therapeutic strategies.

opencc-zeroDec 2014View details →
ClinicalTrials.gov28/100

A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology

ClinicalTrials.gov study NCT04764669. IPD Sharing: YES. Countries: 2. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

ClinicalTrials.gov study NCT04831281. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

ClinicalTrials.gov study NCT02702102. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
dryad28/100

Data from: Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy Body disease

Open the record for dataset details and reuse information.

publicApr 2016View details →
geo24/100

A pattern to rule them all: tracing a human brain map of shared molecular aspects across aging, Alzheimer’s disease and dementia with Lewy bodies

GEO Series GSE280268. Homo sapiens. 90 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenOct 2024View details →
geo24/100

Brain transcriptomic analysis in Parkinson's disease patients stratified by Braak Lewy body stage / Sex differences in Parkinson's disease brain transcriptome

GEO Series GSE216281. Homo sapiens. 84 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenOct 2022View details →
geo24/100

Synaptic vesicle endocytosis deficits underlie GBA-linked cognitive dysfunction in Parkinson’s disease and Dementia with Lewy bodies

GEO Series GSE283187. Mus musculus. 15 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenApr 2025View details →
dryad24/100

Data from: Effects of Lewy body disease and Alzheimer's disease on brain atrophy and cognitive dysfunction

Objectives: We investigated the independent and interaction effects of Alzheimer's disease (AD) and Lewy body disease (LBD) on cognition and brain atrophy. Methods: We consecutively recruited 38 controls and 108 patients with AD-related cognitive impairment (ADCI) and/or LBD-related cognitive impairment (LBCI) from university-based dementia and movement clinics. Diagnoses of ADCI and LBCI were supported by 18F-Florbetaben PET and 18F-FP-CIT-PET, respectively. There were 38 controls, 26 patients with pure ADCI (18 mild cognitive impairment (MCI) and 8 dementia), 28 patients with pure LBCI (13 MCI and 15 dementia), and 54 patients with mixed ADCI and LBCI (17 MCI and 37 dementia). We performed group-wise comparisons for neuropsychological z scores and regional cortical thickness. We also evaluated the effects of ADCI and LBCI using general linear models. Results: Compared to the controls, pure patients with ADCI group and pure LBCI group had focused cortical thinning in the bilateral entorhinal/right anterior temporal cortices and bilateral anteromedial temporal/basal frontal cortices, respectively, while the mixed disease group had additional cortical thinning in the widespread association cortices. The independent effects of ADCI and LBCI on regional cortical thinning overlapped in the widespread association cortices, especially at the bilateral temporo-parietal junction and parietal cortices. ADCI and LBCI had independent detrimental effects on the copying item of the Rey-Osterrieth Complex Figure Test. Conclusions: Concomitant ADCI and LBCI are associated with the accentuation of neurodegeneration to widespread association cortices, and both diseases contribute to visuospatial dysfunction.

opencc-zeroDec 2018View details →
ClinicalTrials.gov24/100

Music Therapy to Prevent Hospital-acquired Delirium in Parkinson's Disease and Dementia With Lewy Bodies

ClinicalTrials.gov study NCT06063161. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.